RxDoctor Payments Data

Enjoli Rogers

Women's Health · Philadelphia, PANPI 1073003760

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Medtronic accounts for 87.5% of it on its own, with 6 other manufacturers making up the rest. Among women's health clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,727in general payments, 2019–2025

Across 48 payments — averaging $56.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Sumitomo Pharma America, Inc.$177
  • 180 Medical, Inc.$64
  • Coloplast$37
  • AbbVie$29
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$22
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$2,727100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,727 in reported general payments places this provider in the 95th percentile of 250 women's health providers in Pennsylvania.

See all women's health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$26,785
Medicare patients
88
Services billed
476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron34$20,950
GemtesaVibegron20$14,072
Estradiol194$12,277
Solifenacin Succinate55$2,977
Methenamine Hippurate24$2,411
Tolterodine Tartrate ErTolterodine Tartrate19$1,773
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst70$946
Trospium Chloride13$485
Metronidazole20$365
NitrofurantoinNitrofurantoin Macrocrystal18$242
Fluconazole22$86

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$177$14,07220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 women's health providers in Pennsylvania.

Other women's health in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →